Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes

BACKGROUND: Current therapy for osteosarcoma pulmonary metastases (PMs) is ineffective. The mechanisms that prevent successful immunotherapy in osteosarcoma are incompletely understood. We investigated the tumor microenvironment of metastatic osteosarcoma with the goal of harnessing the immune syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Ligon, John A, Choi, Woonyoung, Cojocaru, Gady, Fu, Wei, Hsiue, Emily Han-Chung, Oke, Teniola F, Siegel, Nicholas, Fong, Megan H, Ladle, Brian, Pratilas, Christine A, Morris, Carol D, Levin, Adam, Rhee, Daniel S, Meyer, Christian F, Tam, Ada J, Blosser, Richard, Thompson, Elizabeth D, Suru, Aditya, McConkey, David, Housseau, Franck, Anders, Robert, Pardoll, Drew M, Llosa, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144029/
https://www.ncbi.nlm.nih.gov/pubmed/34021032
http://dx.doi.org/10.1136/jitc-2020-001772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144029/
https://www.ncbi.nlm.nih.gov/pubmed/34021032
http://dx.doi.org/10.1136/jitc-2020-001772

Ejemplares similares